Insulin Lispro
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Type 1 Diabetes Mellitus
Conditions
Type 1 Diabetes Mellitus
Trial Timeline
Feb 21, 2019 → Mar 27, 2019
NCT ID
NCT03849612About Insulin Lispro
Insulin Lispro is a pre-clinical stage product being developed by Eli Lilly for Type 1 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT03849612. Target conditions include Type 1 Diabetes Mellitus.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05893797 | Pre-clinical | Completed |
| NCT03890003 | Pre-clinical | Completed |
| NCT03849612 | Pre-clinical | Completed |
| NCT03848767 | Pre-clinical | Completed |
| NCT03743285 | Pre-clinical | Completed |
| NCT02623452 | Phase 1 | Withdrawn |
| NCT02623478 | Phase 1 | Withdrawn |
| NCT02623465 | Phase 1 | Withdrawn |
| NCT03368807 | Pre-clinical | Completed |
| NCT03367390 | Phase 1 | Completed |
| NCT02111083 | Phase 1 | Completed |
Competing Products
20 competing products in Type 1 Diabetes Mellitus